OAK BROOK, Ill.--(BUSINESS WIRE)--Bio-Bridge Science, Inc. (OTCBB: BGES) announced today that it has entered into a cooperative agreement with the Institute of Basic Medical Sciences at the Chinese Academy of Medical Sciences, a leading medical research institute in China, to research and develop a human papillomavirus polyvalent vaccine using prokaryotic expression system. This vaccine is designed to prevent from infection by human papillomavirus types 6, 11, 16, 18, 31, 45, and 58, which is expected to provide broader protection than the current vaccine in the market and have much lower production costs. Under the agreement, Bio-Bridge has been granted the preferential right to develop the vaccine and enjoys a 60% interest in the project.
